Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Lutetium-PSMA

  • <sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&amp;T Therapy
    You have access
    177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
    Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, William Counter, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Aron Poole, Adam Hickey, Shikha Agrawal, Gary Perkins, Annukka Kallinen, Enid Eslick, Martin R. Stockler, Anthony M. Joshua, Andrew Nguyen and Louise Emmett
    Journal of Nuclear Medicine March 1, 2023, 64 (3) 410-415; DOI: https://doi.org/10.2967/jnumed.122.264677
  • Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    You have access
    Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Adam Hickey, Peter Eu, Martin Stockler, Andrew J. Martin, Anthony M. Joshua, Andrew Nguyen and Louise Emmett
    Journal of Nuclear Medicine February 1, 2023, 64 (2) 221-226; DOI: https://doi.org/10.2967/jnumed.122.264398
  • The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    You have access
    The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua and Louise Emmett
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 69-74; DOI: https://doi.org/10.2967/jnumed.122.264104
  • <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
    You have access
    177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
    Sarennya Pathmanandavel, Megan Crumbaker, Andrew O. Yam, Andrew Nguyen, Christopher Rofe, Elizabeth Hovey, Craig Gedye, Edmond M. Kwan, Christine Hauser, Arun A. Azad, Peter Eu, Andrew J. Martin, Anthony M. Joshua and Louise Emmett
    Journal of Nuclear Medicine April 1, 2022, 63 (4) 560-566; DOI: https://doi.org/10.2967/jnumed.121.262552
SNMMI

© 2025 SNMMI

Powered by HighWire